Repeat Ultrasonographic Examinations Reveal Accessory Spleen in a Case with Relapse ITP

Ahmet Sarici*, Ayshe Slocum, Hilal Er Ulubaba, Mehmet Hanifi Kandemir, Mehmet Ali Erkurt, Emin Kaya and İrfan Kuku

Department of Haematology, Turgut Özal Medical Center, Faculty of Medicine, İnönü University, Turkey

*Corresponding author: Ahmet Sarici, Department of Haematology, Turgut Özal Medical Center, Faculty of Medicine, İnönü University, Turkey

Keywords
Primary immune thrombocytopenia, Accessory spleen, Splenectomy

CASE REPORT

Repeat Ultrasonographic Examinations Reveal Accessory Spleen in a Case with Relapse ITP

Ahmet Sarici, Ayshe Slocum, Hilal Er Ulubaba, Mehmet Hanifi Kandemir, Mehmet Ali Erkurt, Emin Kaya and İrfan Kuku

Department of Haematology, Turgut Özal Medical Center, Faculty of Medicine, İnönü University, Turkey

*Corresponding author: Ahmet Sarici, Department of Haematology, Turgut Özal Medical Center, Faculty of Medicine, İnönü University, Turkey

Keywords
Primary immune thrombocytopenia, Accessory spleen, Splenectomy

Introduction

Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated thrombocytopenia (< 100,000/microliters). The pathogenesis of ITP is related to a combination of increased platelet destruction and impaired platelet production caused principally by antiplatelet autoantibodies [1]. ITP is a commonly acquired bleeding disorder which often is a chronic disease in adults. The clinical manifestations of ITP are all mostly related to bleeding and/or thrombocytopenia; fatigue occurs in some patients. In patients newly diagnosed with ITP, treatment is initiated if thrombocyte count is < 30,000/microliters or if bleeding is present. The goal of ITP therapy is to provide a safe platelet count to prevent clinically significant bleeding, rather than to normalize the platelet count. Corticosteroids are the first treatment option. For all patients with persistent ITP who have experienced clinically important bleeding despite first-line therapy with glucocorticoids, second-line therapy should be evaluated. Second-line treatment is initiated in unresponsive patients and/or in the case of relapse ITP [2]. Splenectomy, rituximab and thrombopoietin receptor agonists (TPO-RAs) currently make up the most effective second-line treatments and splenectomy and rituximab are both associated with durable remissions off-treatment. One of the causes of relapse after splenectomy in patients with ITP is the presence of an accessory spleen. Herein, we present a patient who relapsed 3 months after splenectomy and whose accessory spleen was detected 6 years post-splenectomy and at the third abdominal ultrasonography (USG) examination. We aimed to emphasize the importance of insisting on splenic investigation in patients with ITP who have relapsed post-splenectomy.

Case Report

A 45-year-old female patient was evaluated in our outpatient clinic with a complaint of recurrent bruising on her legs. The patient’s initial complete blood count revealed a hemoglobin count of 14.4 g/dL, a white blood cell count of 11,900 × 10^9/liters and a platelet count of 5,000 × 10^9/liters. Thrombocytopenia was confirmed by peripheral blood smear. Other causes of secondary thrombocytopenia were excluded and the patient was diagnosed with immune thrombocytopenia. On physical examination, there were no significant findings except for petechiae and ecchymosis on both lower extremities. The patient was prescribed 1 mg/kg prednisone and partial response to steroid treatment was obtained. The patient ultimately underwent a splenectomy because of the loss of partial response upon follow-up as she demonstrated irregular control thrombocyte measurements. Splenectomy was performed 15 months after the initial diagnosis and a partial response to splenectomy lasting about 3.5 months was observed. A pathological examination of splenectomy material demonstrated

Accepted: August 07, 2019: Published: August 09, 2019
Copyright: © 2019 Sarici A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
marked lymphoid hyperplasia in white pulp and prominence of a large number of macrophages with phagocytosed erythrocytes in the sinusoids of the red pulp, in support of our diagnosis of ITP. Thrombocytopenia repeated 3.5 months after splenectomy and prednisone and azathiopurine were given for 9 months. The patient was then followed for six years without treatment. However, thrombocytopenia repeated after 6 years. The patient was once again prescribed prednisone 1 mg/kg/day in addition to eltrombopag 25 mg/day.

Abdominal USG evaluations performed 6 months post-splenectomy and later 6 years post-splenectomy, did not report presence of an accessory spleen. The third and final abdominal USG of the patient with refractory thrombocytopenia revealed an accessory spleen measuring 1.5 cm (Figure 1). Computed tomography (CT) as well as a magnetic resonance imaging (MRI) performed following the abdominal ultrasonography also confirmed presence of an accessory spleen (Figure 2 and Figure 3). In the case of the patient being presented, the accessory spleen detected in USG, MRI and CT was not observed in 3mCi Tc99m-sulfide colloid scintigraphy. A second splenectomy was planned for removal of the accessory spleen.

**Conclusion**

The aim of treatment in patients with primary immune thrombocytopenia (ITP) is to obtain a safe platelet count to prevent clinically significant bleeding (major bleeding) rather than normalizing the platelet count [3,4]. In light of this information, treatment indications for newly diagnosed ITP patients include, I) Thrombocyte counts below 30,000/microL and II) Platelet counts above 30,000/microL in correlation with clinically significant bleeding.

Corticosteroids make-up the first-line treatment of patients newly diagnosed with ITP. Intravenous immunoglobulin and Anti-(Rh) D are other treatment options. In primary care, standard dose prednisone or methylprednisolone (1-2 mg/kg/day), or high-dose dexamethasone (40 mg/day) is administered as corticosteroid therapy. 65-85% of newly diagnosed ITP patients respond to standard dose prednisone or methylprednisolone [5]. Recently, studies comparing the efficacy of dexamethasone and prednisone treatments have been increasing. These studies have reported that cases diagnosed with ITP respond earlier to dexamethasone treatment and that response rates are higher than those obtained using prednisone [5,6]. However, in a meta-analysis published in 2016, dexamethasone treatment has not been shown to be superior to prednisolone therapy in the long-term and in contrast to the early stages of treatment [7]. Most newly diagnosed ITP patients who respond to corticosteroid treatment have long-term relapse. In patients with ITP who have no response to relapse and/or relapse to first-line treatment, second-line treatment is initiated. Splenectomy, rituximab and thrombopoietin receptor agonists are the most important current second-line treatments.

Approximately 80% of ITP patients respond to splenectomy and in 60-65% of patients this response con-
tinues for many years [8, 9]. On the other hand, nearly 15% of ITP patients that respond to splenectomy develop relapse after splenectomy [10]. As in the case of our patient, most of relapses develop shortly after splenectomy [10, 11]. However, it is reported that relapse may occur up to 30 years post-splenectomy [12]. One of the major causes of relapse post-splenectomy is the presence of an accessory spleen. It is for this reason that evaluations (ultrasonography, computed tomography, etc.) to detect presence of an accessory are routinely performed in patients prior splenectomy. Nevertheless, despite preoperative investigations, routine examination may fail to detect an accessory spleen, or an accessory spleen may be overlooked during splenectomy. In addition, a resting accessory spleen may hypertrophy post-splenectomy to compensate absence of primary splenic tissue. It has been hypothesized that, contamination of neighboring tissues with spleen cells during splenectomy may also cause the development of an accessory spleen [13]. Phom, et al. reported that accessory spleen was detected in 14 (31%) of 45 ITP patients who experienced relapses post-splenectomy [14]. In another study, it is stated that the incidence of accessory spleen can be as high as 50% in cases of relapse after splenectomy [15]. ITP patients who develop relapse due to the presence of an accessory spleen respond to second splenectomy. Therefore, it is recommended that splenectomy be performed again in ITP patients with relapse due to accessory spleen.

Although the patient presented in this study experienced a relapse 3 months after splenectomy, it was only possible to detect accessory spleen after 6 years and at the third ultrasonographic examination. We concluded that the most important reason for detecting accessory spleen in repeat ultrasonographic examinations is associated with compensatory hypertrophy. In conclusion, in patients with ITP who develop relapse post-splenectomy, accessory spleen should be investigated and if the accessory spleen cannot be detected in initial examinations, due to inadequacy of testing methods and the operative skill of the technicians, it would be appropriate to continue the investigation of accessory spleen at close intervals and with persistency.

References


